Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Galecto, Inc. (not Damora Therapeutics, Inc.) on June 20, 2024. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol GLTO.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Voting Results
Stockholders approved three key proposals at the Annual Meeting. The total shares entitled to vote were 27,112,697, with 17,204,181 shares present or represented by proxy.
- Election of Director: Anne Prener, M.D., was elected as a Class I Director to serve until the 2027 Annual Meeting.
- Votes For: 10,651,770
- Votes Withheld: 711,618
- Broker Non-Votes: 5,840,793
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation to authorize a reverse stock split.
- Ratio: Between 1-for-4 and 1-for-25 (exact ratio to be determined by the Board within one year).
- Votes For: 15,283,182
- Votes Against: 1,830,713
- Abstentions: 90,286
- Ratification of Auditors: EY Godkendt Revisionspartnerselskab was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 16,927,703
- Votes Against: 197,148
- Abstentions: 79,330
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard disclosure that the reverse stock split ratio and timing are at the discretion of the Board of Directors. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and effective date once announced by the Board of Directors.
- Confirm the impact of the reverse stock split on share count and trading price.
- Review the full Proxy Statement (filed April 29, 2024) for detailed biographies of the new director and further context on the auditor ratification.
- Monitor future filings for the implementation of the reverse stock split within the authorized one-year window.